Interferon-Combination Strategies for the Treatment of Chronic Hepatitis C

Andrew Aronsohn, MD1 Donald Jensen, MD1

1 Center for Liver Disease, Section of Gastroenterology, Hepatology and Nutrition, University of Chicago Medical Center, Chicago, Illinois

In 2011, the first direct-acting antiviral agents (DAAs) became available for use in the treatment of chronic hepatitis C. In large registration trials, the addition of either telaprevir or boceprevir to peginterferon (PegIFN) and ribavirin (RBV) increased sustained virologic response rates and for many patients allowed for shortened duration of therapy.1,2 Since approval, multicenter postmarketing studies have shown that treatment with first-generation DAAs have resulted in somewhat lower than expected response rates and a relatively high frequency of adverse events while on therapy.3 Upcoming generations of DAAs offer promise of improved efficacy with limited toxicity. Although the ultimate goal in hepatitis C virus (HCV) treatment is simple and effective IFN-free therapy, many second-wave DAAs will still require interferon to achieve acceptable response rates. In this review, we will discuss novel HCV treatment regimens where interferon is combined with the next generation of DAAs [► Table 1].

Protease Inhibitors

During the HCV life cycle, the NS3 protease binds to its NS4A cofactor and plays a key role in the posttranslational processing of the HCV polyprotein.4 Protease inhibitors (PIs) block the catalytic function of the NS3/4A protease, and halt virus production by preventing mature nonstructural viral proteins to be generated. In addition, because the NS3/4A complex is involved in decreasing activity of type 1 IFN though cleavage of IFN-B promoter stimulator-1 (IPS-1), blockage of this complex formation is also thought to stimulate innate immune response.5 Second-wave, first-generation PIs have improved dosing schedules and more tolerable side-effect profiles when compared with telaprevir and boceprevir. Beyond the second-wave PIs, second-generation PIs are expected to have broader genotypic coverage and higher barriers to resistance.6

Simeprevir

Simeprevir (TMC 435) is a potent, second-wave, first-generation NS3/4A PI with antiviral activity in genotypes 1, 2, 4, 5, and 6. The U.S. Food and Drug Administration (FDA) has approved this agent as part of combination therapy for treatment-experienced and treatment-naïve genotype 1 patients. In QUEST 1, a randomized, double-blind placebo controlled trial of treatment naïve patients, response-guided therapy using simeprevir 150 mg daily was administered for 12 weeks combined with PegIFN/RBV for 24 to 48 weeks. Overall, simeprevir-based therapy yielded sustained virologic response (SVR) rates of 80% compared with 50% in patients treated with PegIFN/RBV dual therapy. In this study, 224 of 264 patients (85%) met criteria for response-guided therapy and were able to shorten duration of treatment to 24 weeks. Among patients treated with simeprevir, those with
unfavorable IL28B genotype, advanced fibrosis, and genotype 1a had inferior response rates. Notably, because the presence of a pre-existing Q80K mutation has been shown to significantly reduce response rates, the simeprevir package insert recommends screening patients with genotype 1a HCV for this mutation, and if present, consideration of alternative therapy.

The QUEST 2 trial was a similar randomized, double-blind, placebo controlled trial in treatment-naïve genotype 1 patients, which evaluated impact of type of IFN on response rates (PegIFN-α-2a vs. PegIFN-α-2b). In this trial, 209 of 257 patients (81%) treated with simeprevir achieved SVR with 91% eligible for truncated therapy of 24 weeks. The type of interferon used did not affect response rates. In addition, HCV subtype was not found to be a predictor of SVR in this study (80% SVR12 in genotype 1a vs. 82% SVR12 in genotype 1b). Lower SVR rates were again seen in patients with advanced fibrosis (SVR12: 65–67%); however, these remained

Table 1 Summary of novel DAA/interferon containing HCV regimens

<table>
<thead>
<tr>
<th>Agent</th>
<th>Class</th>
<th>Genotype</th>
<th>Previous treatment</th>
<th>Treatment outcome (SVR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simeprevir</td>
<td>NS3/4A PI</td>
<td>1, 4</td>
<td>Naïve</td>
<td>• QUEST 1: 80%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• QUEST 2: 81%</td>
</tr>
<tr>
<td>MK-5172</td>
<td>NS3/4A PI</td>
<td>1</td>
<td>Naïve</td>
<td>86–91%</td>
</tr>
<tr>
<td>Asunaprevir</td>
<td>NS3/4A PI</td>
<td>1, 4</td>
<td>Naïve</td>
<td>• G1: 64%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• G4: 89%</td>
</tr>
<tr>
<td>Faldaprevir</td>
<td>NS3/4A PI</td>
<td>1</td>
<td>Naïve</td>
<td>• SILEN-C1: 72–84%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• STARTVerso 1/2: 60–88%</td>
</tr>
<tr>
<td>Daclatasvir</td>
<td>NS5A inhibitor</td>
<td>1, 4</td>
<td>Naïve</td>
<td>• COMMAND 1: G1: 58–87%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>G4: 100%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2, 3</td>
<td>Naïve</td>
<td>• COMMAND GT 2/3 G2: 83% G3: 67–69%</td>
</tr>
<tr>
<td>Setrobuvir</td>
<td>NNPI</td>
<td>1</td>
<td>Naïve</td>
<td>Unavailable</td>
</tr>
<tr>
<td>Deleobuvir</td>
<td>NNPI</td>
<td>1</td>
<td>Naïve</td>
<td>Unavailable</td>
</tr>
<tr>
<td>Sofosbuvir</td>
<td>NPI</td>
<td>1, 4, 5, 6</td>
<td>Naïve</td>
<td>• ATOMIC: 87–89%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• NEUTRINO: G1: 82–92%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>G4:100%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>G5: 100% (n = 1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>G6: 100% (n = 6)</td>
</tr>
<tr>
<td>Mericitabine</td>
<td>NPI</td>
<td>1, 4</td>
<td>Naïve</td>
<td>• PROPEL: 33–51%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• JUMP-C: 57%</td>
</tr>
<tr>
<td>Mericitabine/ Danoprevir (QUAD)</td>
<td>NPI/PI</td>
<td>1</td>
<td>Experienced</td>
<td>• MATTERHORN Null: 100% Partial responder: 96%</td>
</tr>
<tr>
<td>Asunaprevir/ Daclatasvir (QUAD)</td>
<td>PI/NS5A inhibitor</td>
<td>1</td>
<td>Experienced</td>
<td>Null: 90–100%</td>
</tr>
<tr>
<td>VX222/Telaprevir (QUAD)</td>
<td>NNPI/PI</td>
<td>1</td>
<td>Naïve</td>
<td>• ZENITH: 82–93%</td>
</tr>
<tr>
<td>Tegobuvir/GS9451 (QUAD)</td>
<td>NNPI/PI</td>
<td>1</td>
<td>Naïve</td>
<td>G1a: 74%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>G1b: 90%</td>
</tr>
</tbody>
</table>

Abbreviations: DAA, direct-acting antiviral agent; HCV, hepatitis C virus; NPI, nucleotide polymerase inhibitor; NNPI, nonnucleoside polymerase inhibitor; PI, protease inhibitor.
Asunaprevir

Asunaprevir (BMS 650032) is a second-wave, first-generation macrocyclic, selective NS3/4A PI with in vitro activity against HCV genotypes 1, 4, 5, and 6. In phase 2a study, asunaprevir was given in combination with PegIFN/RBV at doses ranging from 400 mg/d to 1200 mg/d. SVR24 rates were significantly higher than in the PegIFN/RBV group (SVR24: 83–92% vs. 46%); however, at 12-week analysis, greater frequency of aminotransferase elevations were seen at higher doses and all dosages were decreased to 200 mg twice daily. In phase 2b study, treatment duration and efficacy was evaluated in patients with genotype 1 and 4. Patients received asunaprevir 200 mg twice daily for 12 to 24 weeks combined with PegIFN/RBV for 24 to 48 weeks and were compared with patients receiving PegIFN/RBV dual therapy. In intention-to-treat analysis, 64% of genotype 1 patients treated with asunaprevir containing regimens achieved SVR24 compared with 45% in control arms. In genotype 4 patients, SVR24 was seen in 15 of 17 patients (89%) of patients receiving asunaprevir compared with 43% (3/7) treated with PegIFN/RBV. At the 200 mg twice daily dosage, asunaprevir was generally well tolerated; however, grade 3 to 4 aminotransferase elevations were more frequent in experimental arms (10% vs. 2%). All aminotransferase elevations resolved and none met predetermined Dry Induced Liver Injury (pDILI) criteria.

Faldaprevir

Faldaprevir is a second-wave, first-generation NS3/4A PI with a relatively long half-life, enabling daily dosing. In the phase 2b study SILEN-C1, treatment-naïve, genotype 1 noncirrhotic patients were randomized to receive 24 weeks of PegIFN/RBV combined with faldaprevir 120 mg with a 3-day PegIFN/PBV lead-in, 240 mg daily with a 3-day lead-in, or 240 mg daily without lead-in followed by 24 weeks of PegIFN/RBV. Patients in the 240 mg with group who maintained rapid virologic response (mRVR) were randomized to 24 or 48 weeks of total treatment duration. Overall, SVR was achieved in 72 to 84% of patients treated with faldaprevir compared with 56% in the placebo arm. The majority of patients (78–87%) treated with 240 mg faldaprevir achieved mRVR; however, lower SVR rates (81% vs. 96% p = 0.051) and higher relapse rates (17% vs. 4%) were seen in patients who underwent 24 weeks of total therapy.

In SILEN-2, prior null responders and partial responders to PegIFN/RBV therapy were treated with faldaprevir-containing regimens. Patients were treated with 48 weeks of PegIFN/RBV in combination with faldaprevir 240 mg once daily with a 3-day lead-in of PegIFN/RBV dual therapy, 240 mg daily without lead-in, or 240 mg twice daily with lead-in. In prior partial responders, SVR rates were 32%, 50%, and 42%; in prior null responders, SVR rates were 21%, 35%, and 29% in the faldaprevir 240 mg daily/lead-in, 240 mg daily, and 240 mg twice daily/lead-in groups, respectively. Patients with mRVR were eligible for 24 weeks of therapy; however, similar to SILEN-1, patients treated with truncated duration of therapy had inferior response rates (SVR: 72% vs. 43%; p = 0.035).

In the phase III trials STARTVerso 1 and 2, 1309 genotype 1 treatment naïve patients from Europe, Asia, and North America were treated with either faldaprevir 120 mg or 240 mg daily for 12 to 24 weeks along with PegIFN/RBV for 24 to 48 weeks. SVR12 rates ranged from 60% to 88% and were noted to be highest in Asian cohorts. In STARTVerso 3, 677 prior nonresponders were treated with faldaprevir 240 mg for 12 to 24 weeks along with PegIFN/RBV for 48 weeks. SVR12 rates for patients with prior relapse (70%), partial response (47–58%), and null response (33%) were all significantly higher than PegIFN/RBV control. Of note, relatively low response rates (13–18%) were seen in prior null responders with cirrhosis. Finally, in STARTVerso 4, patients with HCV/
HIV coinfection were studied. Patients received faldaprevir 120–240 mg daily plus PegIFN/RBV with an overall SVR4 rate of 74%.\textsuperscript{19}

Faldaprevir was well tolerated and within the Phase III STARTVerso trials, discontinuation due to adverse events ranged from 4–7%. More common adverse events included increased in bilirubin and phototoxicity.

**NS5A Inhibitors**

NS5A is a 447 amino acid protein that plays a key role in HCV viral replication and viral particle assembly. Inhibition of this protein by novel therapeutic agents has been shown to block RNA replication by effectively disrupting the assembly of the HCV replication complex.\textsuperscript{20}

**Daclatasvir**

Daclatasvir is a potent, first-in-class NS5A inhibitor that has been shown to have pan-genotypic activity.\textsuperscript{21} In COMMAND GT 2/3, patients with HCV genotypes 2 and 3 were treated with daclatasvir 60 mg daily in addition to PegIFN/RBV for either 12 or 16 weeks and were compared with a control group receiving PegIFN/RBV for 24 weeks. Numerically higher SVR24 rates were seen in both genotypes in patients who received daclatasvir (genotype 2: SVR24 = 83% vs. 63% and genotype 3 SVR24 = 67–69% vs. 59%).\textsuperscript{22} In COMMAND-1, patients with genotype 1 (n = 365) and 4 (n = 30) were treated with daclatasvir/PegIFN/RBV regimens. In this study, patients were randomized to receive either 20 mg or 60 mg of daclatasvir for 12 to 24 weeks in combination with PegIFN/RBV for 24 weeks. Among genotype 1 patients treated with daclatasvir 60 mg, SVR12 rates for genotype 1b (87%) were higher than in patients with genotype 1a (58%). This difference is thought to be due to a fivefold higher antiviral potency and a higher genetic barrier to resistance in genotype 1b. Among those with genotype 4 HCV, patients receiving daclatasvir 60 mg had a 100% SVR rate (12 of 12) compared with PegIFN/RBV control arms with a 50% SVR rate (3 of 6 patients). Overall, adverse-event profiles in daclatasvir arms were similar to patients treated with PegIFN/RBV dual therapy with the exception of dry skin, influenza-like illness, and nausea, which were seen more frequently (> 10%) in experimental arms.\textsuperscript{23}

**Nonnucleoside Polymerase Inhibitors**

Nonnucleoside polymerase inhibitors (NNPIs) act as allosteric inhibitors of the RNA-dependent RNA polymerase (NS5B) that catalyzes viral replication. This enzyme has four allosteric binding sites that are potential targets for NNPIs: thumb domain 1 and 2 and palm domain 1 and 2. NNPIs have efficacy in genotype 1 HCV only and when used without other DAAs have a low barrier to resistance.\textsuperscript{24}

**Setrobuvir**

Setrobuvir is a well-tolerated, NNPI that inhibits the palm 1 domain of the NS5B RNA polymerase. In a phase II study, patients received setrobuvir or placebo with PegIFN/RBV for 12 weeks at 200 mg twice daily or 400 mg twice daily, both given with a loading dose of 800 mg every 12 hours on day 1. Those with an undetectable viral load at weeks 4 and 12 were randomized to receive PegIFN/RBV dual therapy for an additional 12 or 36 weeks. Early viral kinetics of setrobuvir arms were superior to PegIFN/RBV arms.\textsuperscript{25} In this study, adverse events in setrobuvir containing arms were similar to controls with the exception of one patient who discontinued setrobuvir due to a grade 3 rash. Because of high rates of relapse, an additional phase II study has recently been completed in which setrobuvir was given for a longer duration in both treatment-naïve and treatment-experienced patients. Results from this trial are pending.\textsuperscript{26}

**Deleobuvir**

Deleobuvir is a NNI that targets the thumb domain 1 and has been studied in combination with PegIFN/RBV in phase Ib trials. The majority of investigation of this drug has been part of IFN-free regimens with the PI faldaprevir.\textsuperscript{27} In a phase 1b, double-blind placebo controlled dose-finding study, both treatment-naïve (n = 27) and treatment-experienced patients (n = 30) were treated with deleobuvir at 400, 600, or 800 mg three times daily dosing. Rapid virologic response rates at day 28 were seen in 11 of 19 treatment-naïve patients and 4 of 30 treatment-experienced patients. Higher response rates were seen on genotype 1b patients. Overall, the 600-mg dosing was found to have the optimal benefit/risk ratio. Three previous nonresponders experienced viral breakthrough while on treatment, all of which developed resistance via an amino acid substitution at P495; however, by the end of follow-up, all patients reverted to wild-type virus. Gastrointestinal and rash/photosensitivity were more common in deleobuvir-containing arms when compared with placebo.\textsuperscript{28}

**Nucleotide Polymerase Inhibitors**

Once phosphorylated, nucleoside or nucleotide analog PIs compete with viral nucleotides during RNA chain elongation and when incorporated, result in chain termination, thereby halting the HCV life cycle. Nucleoside/nucleotide analog polymerase inhibitors have a pan-genotypic coverage and a high barrier to resistance due to the very poor replication capacity of the HCV variants they select.

**Sofosbuvir**

Sofosbuvir acts as a chain terminator within the catalytic site of the NS5B polymerase. It has been approved by the FDA for treatment of genotype 1, 4, 5, and 6 along with PegIFN/RBV and in genotype 2 and 3 patients as an IFN-free regimen with ribavirin only.

Phase 2 studies of sofosbuvir (400 mg daily) plus PegIFN/RBV for 12 to 24 weeks resulted in SVR rates ranging from 87 to 92%.\textsuperscript{29,30} In ATOMIC, an open label, randomized, multicenter phase 2 trial, 316 genotype 1 patients were randomized to receive sofosbuvir 400 mg plus PegIFN/RBV for 12 weeks (cohort A) sofosbuvir plus PegIFN/RBV for 24 weeks (cohort B), or 12 weeks of sofosbuvir plus PegIFN/RBV followed by 12 weeks of either sofosbuvir monotherapy or sofosbuvir plus
ribavirin (cohort C). High response rates were seen in all cohorts (SVR24: cohort A = 89%, cohort B = 89%, cohort C = 87%).

NEUTRINO is a single group, open-label phase 3 study of treatment-naive genotype 1, 4, 5 and 6 patients who were treated for 12 weeks with sofosbuvir plus PegIFN/RBV.\(^{29}\) The overall SVR12 rate was 90% and similar response rates were seen regardless of genotype (SVR12: 92% for genotype 1a, \(n = 225\); 82% for genotype 1b, \(n = 66\); 96% for genotype 4, \(n = 28\); 100% for genotype 5, \(n = 1\); 100% for genotype 6, \(n = 6\)). In multivariate analysis, non-CC IL28B genotype (SVR 12: 87% vs. 98%) and cirrhosis (80% vs. 92%) were significantly associated with reduced response. Among patients enrolled in NEUTRINO, 28 patients received sofosbuvir and had a relapse after initial virologic response at the end of treatment. Posttreatment deep-sequencing analysis was performed, which showed no resistance-associated variants.\(^{31}\)

Overall, sofosbuvir is well tolerated. In NEUTRINO, there was a 2% discontinuation rate due to adverse events in sofosbuvir-containing arms with low overall rates of severe adverse events.\(^{31}\)

**Mericitabine**

Mericitabine is a selective nucleoside analog inhibitor of the NS5B RNA polymerase. In PROPEL, treatment-naive genotype 1 or 4 patients received mericitabine 500 mg twice daily for 12 weeks (Arm A), 1,000 mg BID for 8 weeks (Arm B) or 1000 mg BID 12 weeks (Arms C and D), or placebo (Arm E) in addition to PegIFN/RBV. Patients in arms A to C were able to truncate therapy to 24 weeks if they maintained a viral response from week 4 to 22. All other patients received PegIFN/RBV for 48 weeks. Although viral kinetics at week 4 and 12 were superior to placebo, overall SVR24 rates were similar or lower than placebo (Arm A = 48.8%, Arm B = 42%, Arm C = 32.9%, Arm D = 50.6%, and Arm E = 51.2%). Investigators concluded that longer duration of mericitabine therapy was needed.\(^{32}\)

In JUMP-C, a longer duration of mericitabine was given as 1000 mg twice daily for 24 weeks, along with PegIFN/RBV. In this study, patients who achieved virologic response at weeks 4 and 22 were also eligible for response-guided therapy and stopped all treatment at week 24. All other patients received 48 weeks of therapy. Overall, SVR24 was achieved in 56.8% in mericitabine-treated patients as compared with 36.5% of dual therapy controls. In addition, relatively high relapse rates (27.7%) were seen in patients treated with mericitabine. Of 30 patients who met criteria for resistance monitoring, the S282T mutation was not detected in any samples. Mericitabine was well tolerated as all adverse events seen were typical for PegIFN/RBV therapy and no specific safety concerns were identified.\(^{33}\)

**QUAD Therapy**

Various manufacturers have combined two classes of DAAs with PegIFN/RBV in an effort to create highly potent and shorter-duration treatment regimens that could potentially be effective in difficult to treat populations.

**Mericitabine/Danoprevir/PegIFN/RBV**

Due to a relatively low response rate in mericitabine-containing triple therapy, the MATTERHORN study investigated the combination of mericitabine and ritonavir-boosted danoprevir, a second-wave, first-generation PI, along with PegIFN/RBV as QUAD therapy. Triple therapy of ritonavir/danoprevir with PegIFN and RBV for 24 weeks was administered to genotype 1 patients with prior partial response, yielding an SVR12 rate of 56%. Patients who received this regimen plus the addition of mericitabine were noted to have increased the SVR12 rate to 86%. Among treatment-experienced patients with genotype 1b infection, QUAD therapy resulted in an SVR12 rate of 96% in prior partial responders and 100% in null responders. A 73% SVR12 rate was seen on patients with genotype 1a who were prior null responders. Of patients with either virologic breakthrough or relapse, resistant mutations were associated with danoprevir only (predominantly R155K). This regimen was well tolerated and of the 127 patients who received this QUAD therapy, five reported one or more serious adverse events and three patients discontinued therapy due to any adverse event.\(^{34}\)

In lieu of danoprevir, QUAD therapy containing mericitabine, PegIFN/RBV, and either telaprevir or boceprevir are also under investigation.\(^{35,36}\)

**Asunaprevir/Daclatasvir/PegIFN/RBV**

Although both asunaprevir and daclatasvir are potential candidates for effective IFN-free regimens, the combination of these agents along with PegIFN/RBV has been investigated as therapy for difficult to treat genotype 1 null responders.\(^{37}\)

In 2012, Lok presented results of 41 patients treated with asunaprevir based QUAD therapy. Patients were randomized to receive daclatasvir 60 mg QD plus PegIFN/RBV and asunaprevir at either 200 mg daily or twice daily. Notably, the majority of patients enrolled were genotype 1a (88%). Both QUAD therapy arms were treated for 24 weeks and resulted in high response rates (SVR 24: 90–100%). Although no discontinuations due to adverse events were reported, serious adverse events were more frequent in the treatment arms receiving higher doses of asunaprevir (15% vs. 5%).\(^{38}\)

**VX222/Telaprevir/PegIFN/RBV**

VX-222 is a nonnucleoside polymerase inhibitor, which targets thumb domain 2. In the ZENITH trial, VX-222, was studied as part of a QUAD therapy along with telaprevir (PI) and PegIFN/RBV.\(^{39}\) Fifty-nine treatment naïve, genotype 1, noncirrhotic patients were randomized to receive telaprevir and VX-222 at 100 mg or 400 mg for 12 weeks along with PegIFN/RBV for 12 to 24 weeks based on response. One half of patients receiving the 400-mg dose were eligible for 12 weeks of therapy. At interim analysis, among patients eligible for 12 weeks of therapy, SVR12 was achieved in 82% of patients receiving low-dose VX-222 and 93% of patients receiving the higher 400-mg dose. Patients who required 24 weeks of therapy had similar response rates (SVR12: 83–87%). The most frequent adverse events reported included fatigue, rash, mild gastrointestinal symptoms, anemia, and pruritus.\(^{39}\)
Tegobuvir|GS9451|PegIFN|RBV
Tegobuvir is a nonnucleoside, palm domain 2 polymerase inhibitor that has demonstrated a reduction of HCV RNA of 1.5 log10 IU/mL in patients treated for 8 days of monotherapy.30 Investigators combined this agent with the PI GS-9451 along with PegIFN/RBV in an effort to shorten duration of therapy and improve efficacy.41 One-hundred nineteen noncirrhotic genotype 1 patients were treated with QUAD therapy for 16 to 24 weeks. Of these patients, 29% were IL28B genotype CC and 80% were genotype 1a. In intention to treat analysis, patients treated with quadruple therapy had an SVR24 rate of 79%. Notably, patients with genotype 1a subtype had inferior response rates when compared with genotype 1b (SVR24: 74% vs. 90%). Grade 3 adverse events were seen in 19% of patients treated with tegobuvir-based QUAD therapy and 29% developed neutropenia defined as neutrophils < 750/mm3.41

Conclusions
Multiple DAAs in development show promise as effective treatment for HCV. Although IFN remains a backbone of many new regimens, the addition of these novel agents are likely to result in increased tolerability and efficacy when compared with the current standard of care. Interferon-free therapy may be available and effective for some, however, the use of IFN, especially when coadministered with multiple DAAs, may continue to be a necessity for many difficult to treat patients.

Disclosures
Andrew Aronsohn, MD: Nothing to disclose.
Donald Jensen, MD: Research grants: Abbvie, Boehringer-Ingelheim, BMS, Genentech, Gilead, Janssen. Consultations: Boehringer-Ingelheim, BMS, Idenix, Janssen

References
1 Jacobson I, Dore G, Foster G, Fried M. Simeprevir (TMC455) with peginterferon/ribavirin for chronic hcv genotype 1 infection in treatment-naive patients: results from QUEST-1, a Phase III trial. Paper presented at: The 48th Annual Meeting of the European Association for Study of the Liver Amsterdam; April 24–28, 2013; Amsterdam, The Netherlands
3 Manns M, Marcellin P, Poordad F, Addonzo de Araujo E. Simeprevir (TMC455) with peginterferon-a2a or -a2b and ribavirin in treatment-naive HCV genotype 1 patients: QUEST-2, a randomised phase III trial. Paper presented at: The 48th Annual Meeting of the European Association for Study of the Liver Amsterdam; April 24–28, 2013; Amsterdam, The Netherlands
11 Jensen D, Asselah TD, D., Foster GR. A pooled analysis of two randomized, double-blind placebo-controlled Phase III trials (STARTVerso1&2) of faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C genotype-1 infection. Paper presented at: AASLD The Liver Meeting; November 1–5, 2013; Washington, DC
Interferon-Combination Strategies for the Treatment of Chronic Hepatitis C

Aronsohn, Jensen

23 Hezode C, Hirschfield GM, Chesequere W, Sievert W. Daclatasvir, an NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment-naïve HCV-genotype 1 or 4 patients: phase 2b COMMAND-1 SVR12 results. Paper presented at: AASLD The Liver Meeting; November 9–13, 2012; Boston, MA
26 Available at: A study of setrobuvir in combination with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin) in patients with genotype 1 chronic hepatitis C. Available at: www.clinicaltrials.gov. Accessed December 27, 2013
34 Feld J, Jacobson I, Jensen D, Foster G. Up to 100% SVR4 rates with ritonavir-boosted danoprevir (DNvR), mericitabine and ribavirin with or without peginterferon alfa-2a (40kD) in HCV genotype 1-infected partial and null responders: results from the MATTERHORN study. Paper presented at: AASLD The Liver Meeting; November 9–13, 2012; Boston, MA
38 Lok AS, Hezode C, Lawitz E, Gardiner DF. Sustained virologic response in chronic HCV genotype (GT) 1-infected null responders with combination of daclatasvir (DCV; NS5A inhibitor) and asunaprevir (ASV; NS3 Inhibitor) with or without peginterferon alfa-2a/ribavirin (PEG/RBV). Paper presented at: AASLD The Liver Meeting; November 9–13, 2012; Boston, MA
41 Pol S, Jablowski M, Trenkle J, Kanwar B. Antiviral efficacy of the once daily NS3 protease inhibitor GS-9451, the non-nucleoside NS5B inhibitor tegobuvir (GS-9190), and pegylated interferon + ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection. Paper presented at: The 48th Annual Meeting of the European Association for Study of the Liver Amsterdam; April 24–28, 2013; Amsterdam, The Netherlands